DDB2 and cancer: DDB2 expression was positively correlated with the half-maximal inhibitory concentration (IC50) values for doxorubicin, cisplatin, and 5-FU across pan-cancer cell lines, indicating that higher DDB2 levels are associated with reduced drug sensitivity (Figure 2B-2D and Supplementary Figure S5A-S5C).